Keyphrases
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Hepatocellular Carcinoma
52%
Hepatitis C Virus
47%
Liver
38%
Liver Transplantation
37%
Immune Regulation
28%
Hepatitis C Virus Infection
28%
Laparoscopic Sleeve Gastrectomy
24%
Colitis
23%
Nonalcoholic Steatohepatitis
22%
Odds Ratio
22%
Lymphocytes
20%
Extractable Protein
19%
Transplantation
19%
Hepatitis C
17%
Fibrosis
17%
Cirrhosis
17%
Primary Sclerosing Cholangitis
17%
Serum Levels
16%
Inflammatory Bowel Disease
16%
Liver Fibrosis
15%
CD4+
13%
Crohn's Disease
13%
COVID-19
13%
Amiodarone
13%
Adoptive Transfer
13%
Experimental Colitis
13%
Elevated Alanine Aminotransferase
12%
Endoplasmic Reticulum Stress (ER stress)
12%
New Onset
12%
Liver Disease
12%
Liver Damage
12%
Israel
12%
Kidney Transplant Recipients
11%
Phase I Clinical Trial
11%
Transarterial Chemoembolization
11%
Opioid Agonist Treatment
11%
Humoral Response
11%
Primary Biliary Cholangitis
11%
Biliary Epithelial Cells
11%
Hepatitis B Surface Antigen (HBsAg)
11%
Microbiome
11%
Ribavirin
11%
Insulin Resistance
11%
Body Mass Index
11%
Metabolic Syndrome
10%
NK1.1
10%
Obesity
10%
Placebo
10%
Hepatocytes
10%
Medicine and Dentistry
Nonalcoholic Fatty Liver
65%
Hepatocellular Carcinoma
48%
Hepatitis C Virus
37%
Liver Transplantation
34%
Fibrosis
26%
Colitis
24%
Prevalence
23%
Hepatitis C
21%
Infection
20%
Liver Cirrhosis
18%
Fatty Liver
17%
Disease
17%
Natural Killer T Cell
16%
Hepatitis B Virus
16%
Neoplasm
16%
Lymphocyte
16%
Liver Injury
15%
Liver Disease
14%
Body Mass Index
14%
Laparoscopic Sleeve Gastrectomy
13%
Transplantation
13%
Antivirus Agent
13%
Epithelial Cell
13%
Liver Fibrosis
12%
Clinical Trial
12%
Experimental Colitis
12%
Adoptive Transfer
12%
Intraductal Papillary Mucinous Tumor
12%
Prospective Study
12%
Odds Ratio
12%
Ribavirin
11%
Colorectal Adenoma
11%
Chronic Hepatitis C
11%
Transcatheter Arterial Chemoembolization
11%
Humoral Immunity
11%
Kidney Graft
11%
CD8 Antigen
11%
Bacteremia
10%
Steatohepatitis
10%
Pancreas Islet Cell Tumor
10%
Hepatocyte
10%
Inflammatory Bowel Disease
10%
Population
10%
Immunoregulation
10%
Surgery
9%
Immunosuppressive Treatment
9%
Hepatitis C Virus Genotype 1
9%
Non-Alcoholic Fatty Liver Disease
9%
Primary Sclerosing Cholangitis
8%
Public Health
8%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
53%
Hepatitis C Virus
49%
Hepatitis C
32%
Liver Cell Carcinoma
30%
Infection
27%
Fibrosis
24%
Liver Injury
21%
Placebo
20%
Mouse
19%
Prevalence
19%
Fatty Liver
18%
Clinical Trial
17%
Ribavirin
15%
Chronic Hepatitis C
14%
Colitis
14%
Disease
13%
Hepatitis B Virus
13%
Hepatotoxicity
13%
Amiodarone
12%
Neoplasm
12%
Crohn's Disease
12%
Antivirus Agent
12%
Liver Cirrhosis
12%
Liver Disease
11%
Grazoprevir
11%
Elbasvir
11%
Opiate Agonist
11%
Hepatitis C Virus Genotype 1
11%
Adverse Event
11%
Alanine Aminotransferase
10%
Tumor Necrosis Factor
9%
Liver Fibrosis
8%
Primary Sclerosing Cholangitis
8%
Experimental Colitis
8%
HIV
8%
Remission
8%
Ulcerative Colitis
8%
SARS Coronavirus
7%
Inflammatory Bowel Disease
7%
Sortilin
7%
Bacteremia
7%
Endocannabinoid
7%
Probiotic Agent
7%
Proteinase Inhibitor
7%
Immunosuppressive Agent
6%
Impaired Glucose Tolerance
6%
Polyp
6%
2-Arachidonoylglycerol
6%
Reinfection
6%
Fatty Acid
5%
